Gene · 6870
Papers1,207
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,207
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Genetic landscape of a neonatal hypogonadotropic hypogonadism series: Novel variants and phenotypic spectrum. | J Neuroendocrinol | 2026 | 42786427 | PubTator, text mining | PubMed |
| Substance P and PACAP activate dural mast cells through MRGPRX2, not NK1R or PAC1/VPAC receptors. | Cephalalgia | 2026 | 42627518 | PubTator, text mining | PubMed |
| Real-world safety signals of fezolinetant in women with menopausal vasomotor symptoms: a pharmacovigilance analysis of the WHO VigiAccess database. | Menopause | 2026 | 42610452 | PubTator, text mining | PubMed |
| Real-world safety profile of fezolinetant: a disproportionality analysis based on the FAERS database. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | 42547587 | PubTator, text mining | PubMed |
| Precocious puberty in boys: current insights into etiology, genetic advances, and environmental factors. | Front Endocrinol (Lausanne) | 2026 | 42534783 | PubTator, text mining | PubMed |
| Identification of a Novel Splice-Site variant in TACR3 (c.888 + 1G > A) Associated with Asthenozoospermia and Hypogonadotropic Hypogonadism in an Iranian Family. | Reprod Sci | 2026 | 42521916 | PubTator, text mining | PubMed |
| Podcast: Patient voices and clinical advances-Elinzanetant for menopause symptom management associated with breast cancer treatment in the OASIS-4 trial. | Womens Health (Lond) | 2026 | 42515941 | PubTator, text mining | PubMed |
| Neurokinin 3 Receptor Antagonists for Menopause Symptom Management. | Obstet Gynecol Clin North Am | 2026 | 42508870 | PubTator, text mining | PubMed |
| TACR3 variant confers resilience to aging and Alzheimer's disease. | medRxiv | 2026 | 42326829 | PubTator, text mining | PubMed |
| Neurokinin pathway antagonists for vasomotor symptoms in women with breast cancer: focus on elinzanetant and fezolinetant. | Breast | 2026 | 42160911 | PubTator, text mining | PubMed |
| Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications. | J Endocr Soc | 2026 | 42137787 | PubTator, text mining | PubMed |
| Hot flushes during ADT for prostate cancer - a clinical rationale for a neurokinin 3 receptor antagonist. | Nat Rev Urol | 2026 | 42050224 | PubTator, text mining | PubMed |
| Elinzanetant: Defining the Role of Dual Neurokinin-1 and Neurokinin-3 Receptor Antagonism for Management of Vasomotor Symptoms in Menopause. | J Menopausal Med | 2026 | 42045091 | PubTator, text mining | PubMed |
| Elinzanetant: A Nonhormonal Treatment Option for Vasomotor Symptoms Associated With Menopause. | J Pharm Technol | 2026 | 42024036 | PubTator, text mining | PubMed |
| Neurokinin receptor antagonists for vasomotor symptoms: from KNDy neurons to clinical translation. | Nat Rev Endocrinol | 2026 | 41981275 | PubTator, text mining | PubMed |
Efficacy and safety of GS1-144, a novel neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms associated with menopause in Chinese women: a randomized, double-blind, placebo-controlled phase 2 trial. | Menopause | 2026 | 41979542 | PubTator, text mining | PubMed |
| Clinical Pharmacokinetics, Mass Balance and Metabolism of Fezolinetant in Postmenopausal Women. | Eur J Drug Metab Pharmacokinet | 2026 | 41954728 | PubTator, text mining | PubMed |
| Idiopathic Hypogonadotropic Hypogonadism with a Rare Hemi-Arrhinia: A Case Report with Nasal Reconstruction. | J Otolaryngol Head Neck Surg | 2026 | 41902607 | PubTator, text mining | PubMed |
| Explainable drug side effect prediction in central neural system via biologically informed graph neural network. | Transl Psychiatry | 2026 | 41876492 | PubTator, text mining | PubMed |
| Where do neurokinin receptor antagonists fit into management of menopausal vasomotor symptoms? | JAAPA | 2026 | 41874087 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6870/papers